P=N/A, N=60, Completed, Singapore General Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jul 2025

P4, N=2174, Active, not recruiting, Duke University | Recruiting --> Active, not recruiting

P=N/A, N=50, Not yet recruiting, Universidade do Porto | Initiation date: Mar 2026 --> Jul 2026

Furthermore, intraperitoneal injection of minocycline (40 mg/kg) with ACR reduced the levels of MDA, IL-1β, and caspase-3-cleaved proteins in the cerebral cortex. Administration of minocycline exhibits both prophylactic and therapeutic properties against ACR-induced neurotoxicity primarily through anti-oxidant, anti-apoptotic, and anti-inflammatory properties.

This study aimed to investigate the anticancer potential of three tetracycline analogues chemically modified tetracycline-3 (COL-3), doxycycline (DOX), and minocycline (MIN) in leukemia models, with a particular focus on their cytotoxic effects and modulation of the JAK2/STAT3 signaling pathway. Among them, COL-3 emerges as the most potent analogue and acts through both JAK/STAT-dependent and -independent mechanisms. This work supports further investigation of COL-3 as a candidate for drug repurposing strategies in hematological malignancies.

Bacterial adhesion was quantified by colony-forming unit (CFU) counting, and intracellular survival was assessed using a gentamicin protection assay...Interferon-γ expression was mainly induced by pretreatment, whereas tumor necrosis factor-α and interleukin-10 were modulated under cotreatment conditions. These findings indicate that S. boulardii modulates macrophage antimicrobial gene expression and suggest that probiotic pretreatment enhances innate immune responses against intracellular bacterial infections.

The alarming rise in multidrug-resistant (MDR) strains, particularly against clarithromycin (CLR), metronidazole (MNZ), and levofloxacin (LVX), has severely compromised standard therapies. The engineered D-peptide DT7-3 is a potent candidate for combating MDR H. pylori. Its multifaceted mechanism, targeting bacterial viability while suppressing core virulence factors, positions it as a robust lead compound for next-generation eradication therapies aimed at reducing the burden of H. pylori-associated diseases.

P4, N=40, Recruiting, Texas Tech University Health Sciences Center, El Paso

We report a case of a 42-year-old patient with EVI1-positive AML harboring the MLL-AF6 fusion gene, who failed to achieve remission after undergoing standard "IA" induction therapy and was then treated with VAH (venetoclax, azacitidine, and homoharringtonine) consolidation chemotherapy. This case suggests that the combination of ATRA with the VAH regimen may demonstrate promising efficacy and an acceptable safety profile in patients with EVI1-positive AML who are refractory to conventional chemotherapy. However, further clinical studies are required to confirm its wider applicability.

P=N/A, N=246, Terminated, Poitiers University Hospital | N=1100 --> 246 | Trial completion date: Feb 2024 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Oct 2025; The study was stopped due to recruitment difficulties

P=N/A, N=70, Recruiting, Peking University First Hospital | Not yet recruiting --> Recruiting

P3, N=865, Recruiting, MicuRx | N=644 --> 865